Fox Run Management’s Artiva Biotherapeutics ARTV Stock Holding History

Fox Run Management’s Portfolio ARTV Stock Details ARTV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$200K	Buy	+28,022	New	+$283K	0.02%	860

Other funds holding ARTV

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Propel Bio Management Los Angeles, California $189M AUM 71.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Blue Owl Capital Holdings New York $548M AUM 35.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $3.16B AUM 31.44% 1-Year Est. Return

Revelation Capital Management Sausalito, California $8.01M AUM 49.3% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Fox Run Management's ARTV Position: Q3 2026 in Review

Fox Run Management opened a new position in Artiva Biotherapeutics (ARTV) in Q3 2026: 28,022 shares worth $200K. The stake represents 0.02% of the portfolio and ranks #860 among its holdings.

57 funds tracked by Wall St. Rank hold ARTV as of Q3 2026.

Fox Run Management held 28,022 shares of Artiva Biotherapeutics worth $200K as of Q3 2026.
Artiva Biotherapeutics was a new Fox Run Management position in Q3 2026.
Artiva Biotherapeutics made up 0.02% of Fox Run Management's portfolio in Q3 2026, its #860 holding.
57 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2026.

Based on Fox Run Management's 13F filing for Q3 2026, filed 12 Nov 2026.